Diabetic Neuropathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Diabetic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions.
Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain. Predisposing factors include obesity, hypertension, high lipid and sugar levels, and smoking. It may be managed by medication and dietary modification.
The Diabetic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Diabetic Neuropathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 54 molecules, with 52 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Diabetic Neuropathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Diabetic Neuropathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Diabetic Neuropathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abalone Bio IncAchelios Therapeutics Inc
AISA Pharma Inc
Applied Therapeutics Inc
Athira Pharma Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals Inc
Biogen Inc
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Federal University of Minas Gerais
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Lohocla Research Corp
Medifron DBT Co Ltd
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Nervosave Therapeutics
Omeros Corp
Ono Pharmaceutical Co Ltd
PharmAbcine Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Releviate Therapeutics
SGN Nanopharma Inc
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sino Biopharmaceutical Ltd
Sonnet BioTherapeutics Holdings Inc
TMS Co Ltd
VCANBIO Cell and Gene Engineering Corp Ltd
Vertex Pharmaceuticals Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Diabetic Neuropathy reports